SCHEMBL16769984

SCHEMBL16769984

Nc1ncnc2c1c(Br)cn2C1CCOCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 3/20 0.58
SRC P12931 7/20 0.56
LCK P06239 3/20 0.56
TEK Q02763 2/20 0.56
HCK P08631 1/20 0.56
ADK P55263 4/20 0.52
ABL1 P00519 5/20 0.50
METTL3 Q86U44 5/20 0.50
DAPK3 O43293 1/20 0.50
MAP4K4 O95819 1/20 0.50
PAK4 O96013 1/20 0.50
FYN P06241 1/20 0.50
CSF1R P07333 1/20 0.50
IGF1R P08069 1/20 0.50
FGFR1 P11362 1/20 0.50
PRKACA P17612 1/20 0.50
FLT1 P17948 1/20 0.50
LTK P29376 1/20 0.50
KDR P35968 1/20 0.50
MAP2K2 P36507 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29780883 1.00 RET (0.58) RETSRCLCKTEKHCK
SCHEMBL18640804 0.90 SRC (0.59) RETSRCLCKADKABL1
SCHEMBL25612151 0.87 SRC (0.61) RETSRCLCKTEKADK
SCHEMBL870154 0.86 METTL3 (0.58) RETSRCLCKTEKADK
SCHEMBL1786788 0.83 RET (0.58) RETSRCLCKTEKHCK
SCHEMBL29780875 0.83 ADK (0.52) RETSRCLCKTEKHCK
SCHEMBL16769982 0.83 ADK (0.52) RETSRCLCKTEKHCK
SCHEMBL18925745 0.83 METTL3 (0.50) RETADKABL1METTL3KDR
SCHEMBL16769693 0.83 METTL3 (0.50) RETADKABL1METTL3KDR
SCHEMBL17085734 0.82 ADK (0.51) RETSRCLCKTEKHCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116583287-A Pyridazinone heterocyclic compound, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2023-08-11 CN disclosed
US-20170158697-A1 Protein Kinase Inhibitors PHARMASCIENCE INC. (CA) 2017-06-08 US disclosed
US-20170158697-A1 Protein Kinase Inhibitors PHARMASCIENCE INC. (CA) 2017-06-08 US disclosed
WO-2015077866-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE INC. (CA) 2015-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158697-A1 Protein Kinase Inhibitors TEC, LCK, SRC RET 284/4885SRC 3/4885LCK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.